assayed erythrocyte galactokinase and uridyltransferase activities in 12 families with children suffering early onset cataracts. We did not observe any abnormality of galactose metabolising enzymes in either the mothers or the infants. Furthermore, we have looked for the occurrence of cataracts among children of seven mothers heterozygous for one of these two deficiencies. No children with enzyme activity in the normal or heterozygous range had cataracts.
Two genetically determined disorders involving an enzymatic defect in the main galactose metabolic pathway (Figure) Control values (mean (2 SD)) for galactokinase activity in adults and children above 2 years of age were 28-5 [tmol/min/kg haemoglobin (n=87).
Galactokinase activity of the infant is three times higher: it decreased during the first year of life; at one year its level is about 1-5 times the adult value.9
Control values (mean (2 SD)) for uridyltransferase activity were 421 (132) [tmol/min/kg haemoglobin (n=128) for infants, children, and adults.
Haematological counts were performed to detect patients with microcytic anaemia or a high reticulocyte count.
Results
The results are presented in Tables 1 and 2 . Group 1. In the families whose children had cataracts (families 1-12) we did not observe significantly reduced galactokinase or uridyltransferase activities in either the mothers or the offspring. The mean values of these enzymes in the mothers were not significantly different from the control means. Group 2. In the families with mothers having partial galactokinase deficiency (families 13 and 14) or partial uridyltransferase deficiency (families [15] [16] [17] [18] [19] no cataracts were found in the children in the absence of an homozygote defect. In some healthy children enzymatic activities were not assayed.
Discussion
We have explored two groups of patients.
The first group presented 'inexplicable' and early onset cataracts in children with normal galactokinase and uridyltransferase activities. We did not find any abnormalities of galactose metabolism in their mothers.
The second group had a partial galactose metabolism deficiency in the mother. No children of these women had cataracts (except the galactosaemic homozygotes). All the pregnancies were allowed to proceed without any restriction of the diet. Nothing is known of the actual milk intake of these mothers during their pregnancy.
These results are disappointing compared with previously reported findings, which hypothesised that a partial enzymatic deficiency in the mother might be responsible for the inexplicable cataracts in some children. 6
Harley et al have measured galactokinase and uridyltransferase activities in erythrocytes from children with unexplained cataracts, their parents, and matched controls.5 The mean galactokinase activity in the mothers was significantly lower than that of women controls. No such difference could be shown between the children with cataracts or their fathers and the control group. In our experience the mean galactokinase activity in the mothers with children who had cataracts was not significantly different from the control mean. Winder et al have reported partial maternal deficiency of galactokinase and transferase activities in 10 families with early onset cataracts.6 In three families a low lactose diet was prescribed during subsequent pregnancies: two unaffected children were born, but a child with cataracts arose from the third pregnancy. In contrast, our results show that our seven heterozygote mothers had normal children despite the absence of any dietary restriction.
Although plasma lactose concentration (and urinary lactose excretion) increase from the 18th week of pregnancy, it is doubtful whether an appreciable proportion of the circulating lactose is converted into circulating glucose and galactose. Intravenous administration of lactose has been reported not to raise blood glucose concentrations in humans and rats.'2 During pregnancy excretion of galactose is not above normal even in women with a reduced galactose metabolism. '3 The galactokinase activity in the fetal liver is greater than in the adult organ and is reported to be more responsive to plasma galactose concentration.'4 ' This may well offer a measure of protection to the fetal lens.
The development of cataracts in the fetus is likely to be the final common pathway of a variety of biochemical insults. Previous studies in the rat noted histological evidence of damage to the fetal lens when pregnant women ingested a diet unusually rich in galactose (40%). 16 In human beings cataract formation in the fetus of an heterozygous mother probably depends on several factors, such as large milk intake, maternal hepatic dysfunction, or mild biochemical 'intolerance'. After an intravenous loading test with 0-35 g/kg body weight, the half life of galactose and excretion of galactitol are significantly increased in some individuals heterozygous for galactokinase deficiency. 17 
18
Protective mechanisms, however, seem to exist in the fetus. The history of family 19 argues for a specific fetal protection. An heterozygous woman for uridyltransferase deficiency developed cataract during the third trimester of her first pregnancy, and again during her second pregnancy. The two children born of these two pregnancies had normal lenses, the first one was heterozygous for uridyl-transferase activity, the second had normal enzymatic activities. A similar observation has been previously described. '9 In contrast to other studies, our results do not suggest any direct link between maternal partial galactose disorders and infantile cataracts. More data are needed, however, before previous findings can be ascribed to fortuitous associations. 
